5 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)Neoplasms by Histologic Type, basal cell carcinoma, basal cell neoplasm, carcinoma, epithelial neoplasm, neoplasmActive, not recruitingPhase 22026-09-17NCT06422936
Usefulness of Thromboelastography as a Predictor of Prognosis in Patients Undergoing Surgery for Glial Tumors and of the Risk of Postoperative Thromboembolic Disease (GliTEM)Embolism, Embolism and Thrombosis, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, disease, epithelial neoplasm, glioma, lung disorder, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor, pulmonary embolism, respiratory system disorder, thrombotic disease, vascular disorderRecruitingNot stated2026-09-10NCT07813377
INSIGHTFUL-FFR Clinical TrialArterial Occlusive Diseases, acute coronary syndrome, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorderRecruitingPhase 42026-01-12NCT05437900
Spanish-Portuguese Thrombotic Thrombocytopenic Purpura RegistryCytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin Manifestations, blood coagulation disease, blood platelet disease, hematologic disorder, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombophilia, thrombotic microangiopathy, thrombotic thrombocytopenic purpuraRecruitingNot stated2024-05-29NCT05914441
First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive LymphomaHemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasmNot yet recruitingEarly phase 12023-10-26NCT06097455